CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
白细胞介素-6 的关联：认识 CAR-T 细胞治疗后的巨细胞病毒再激活
英文原题：The interleukin-6 connection: Understanding cytomegalovirus reactivation following CAR-T-cell therapy.
查看英文原题
The interleukin-6 connection: Understanding cytomegalovirus reactivation following CAR-T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在84例急性淋巴细胞白血病、非霍奇金淋巴瘤或多发性骨髓瘤患者中，22例在接受嵌合抗原受体修饰T（CAR-T）细胞治疗后出现巨细胞病毒（CMV）病毒血症，比例为26%，中位再激活时间为15.5天。持续高水平白细胞介素-6（IL-6）是CMV再激活的显著危险因素，在不同诊断和靶点亚组间无显著交互作用。其他危险因素包括3级细胞因子释放综合征（CRS）、靶向B细胞成熟抗原（BCMA）的CAR和大剂量皮质类固醇。CRS期间过量的IL-6在CAR-T 细胞免疫治疗后频繁发生的CMV再激活中起重要作用。
展开英文摘要原文
Of 84 patients with acute lymphoblastic leukaemia, non-Hodgkin lymphoma or multiple myeloma, 22 developed cytomegalovirus (CMV) viraemia following chimeric antigen receptor modified T (CAR-T) cell therapy, resulting in a proportion of 26% and a median time to reactivation of 15. 5 days.
Sustained high level of interleukin-6 (IL-6) is a significant risk factor for CMV reactivation without significant interaction across subgroups of diagnosis and target. Other risk factors include 3 grade cytokine release syndrome (CRS), B-cell maturation antigen (BCMA)-directed CAR and high-dose corticosteroids. Excessive IL-6 during CRS play an important role in the frequent CMV reactivation following CAR-T-cell immunotherapy.
论文信息
- 作者
- Li L、Wang Z、Qian C、Xu J、Zhu Z、Chen G、Lu T、Wang Y
- 单位
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.China
- 期刊
- British journal of haematology2026 Feb
- 原文标识
- PubMed 41224498 · DOI 10.1111/bjh.70246